title: Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation.
abstract: Disparity for the minor histocompatibility antigen HA-1 between patient and donor has been associated with an increased risk of acute graft-versus-host disease (GvHD) after allogeneic human leucocyte antigen (HLA)-identical sibling donor stem cell transplantation (SCT). However, no data concerning the impact of such disparity on chronic GvHD, relapse or overall survival are available. A retrospective multicentre study was performed on 215 HLA-A2-positive patients who received an HLA-identical sibling SCT, in order to determine the differences in acute and chronic GvHD incidence on the basis of the presence or absence of the HA-1 antigen mismatch. Disease-free survival and overall survival were also analysed. We detected 34 patient-donor pairs mismatched for HA-1 antigen (15.8%). Grades II-IV acute GvHD occurred in 51.6% of the HA-1-mismatched pairs compared with 37.1% of the non-mismatched. The multivariate logistic regression model showed statistical significance (P: 0.035, OR: 2.96, 95% CI: 1.07-8.14). No differences were observed between the two groups for grades III-IV acute GvHD, chronic GvHD, disease-free survival or overall survival. These results confirmed the association between HA-1 mismatch and risk of mild acute GvHD, but HA-1 mismatch was not associated with an increased incidence of chronic GvHD and did not affect relapse or overall survival.
authors.affiliation: Alloreactivity Unit of the Institut Català d'Oncologia, Hospital Durán i reynals, Avda. Gran via s/n, km 2.7, 08907 L'Hospitalet, Barcelona, Spain. 27532dgg@comb.es
authors.forename: D
authors.initials: D
authors.lastname: Gallardo
authors.forename: J I
authors.initials: JI
authors.lastname: Aróstegui
authors.forename: A
authors.initials: A
authors.lastname: Balas
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.forename: E
authors.initials: E
authors.lastname: Carreras
authors.forename: S
authors.initials: S
authors.lastname: Brunet
authors.forename: A
authors.initials: A
authors.lastname: Jiménez
authors.forename: R
authors.initials: R
authors.lastname: Mataix
authors.forename: D
authors.initials: D
authors.lastname: Serrano
authors.forename: C
authors.initials: C
authors.lastname: Vallejo
authors.forename: G
authors.initials: G
authors.lastname: Sanz
authors.forename: C
authors.initials: C
authors.lastname: Solano
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez-Luaces
authors.forename: J
authors.initials: J
authors.lastname: Marín
authors.forename: J
authors.initials: J
authors.lastname: Baro
authors.forename: C
authors.initials: C
authors.lastname: Sanz
authors.forename: J
authors.initials: J
authors.lastname: Román
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: J
authors.initials: J
authors.lastname: Martorell
authors.forename: J
authors.initials: J
authors.lastname: Sierra
authors.forename: C
authors.initials: C
authors.lastname: Martín
authors.forename: R
authors.initials: R
authors.lastname: de la Cámara
authors.forename: A
authors.initials: A
authors.lastname: Grañena
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000276:immunology / Q000628:therapy; D016009:Chi-Square Distribution; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens / Q000276:immunology*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000628:therapy; D009842:Oligopeptides; D015996:Survival Rate; D014181:Transplantation Immunology
chemical_list: C110615:HA-1 antigen; D015778:Minor Histocompatibility Antigens; D009842:Oligopeptides